Bio-Rad Laboratories Statistics
Share Statistics
Bio-Rad Laboratories has 28.03M shares outstanding. The number of shares has increased by 15.96% in one year.
| Shares Outstanding | 28.03M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -2.26% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 23.44M |
| Failed to Deliver (FTD) Shares | 578 |
| FTD / Avg. Volume | 0.2% |
Short Selling Information
The latest short interest is 651.70K, so 2.32% of the outstanding shares have been sold short.
| Short Interest | 651.70K |
| Short % of Shares Out | 2.32% |
| Short % of Float | 2.78% |
| Short Ratio (days to cover) | 3.36 |
Valuation Ratios
The PE ratio is -14.8 and the forward PE ratio is 31.29.
| PE Ratio | -14.8 |
| Forward PE | 31.29 |
| PS Ratio | 3.53 |
| Forward PS | 3.5 |
| PB Ratio | 1.08 |
| P/FCF Ratio | 43.21 |
| PEG Ratio | n/a |
Enterprise Valuation
Bio-Rad Laboratories Inc. has an Enterprise Value (EV) of 10.84B.
| EV / Earnings | -17 |
| EV / Sales | 4.06 |
| EV / EBITDA | -17.82 |
| EV / EBIT | 29.63 |
| EV / FCF | 49.65 |
Financial Position
The company has a current ratio of 5.83, with a Debt / Equity ratio of 0.14.
| Current Ratio | 5.83 |
| Quick Ratio | 4.34 |
| Debt / Equity | 0.14 |
| Total Debt / Capitalization | 11.98 |
| Cash Flow / Debt | 0.32 |
| Interest Coverage | 7.4 |
Financial Efficiency
Return on equity (ROE) is -0.07% and return on capital (ROIC) is 2.7%.
| Return on Equity (ROE) | -0.07% |
| Return on Assets (ROA) | -0.05% |
| Return on Capital (ROIC) | 2.7% |
| Revenue Per Employee | 346.92K |
| Profits Per Employee | -82.77K |
| Employee Count | 7.70K |
| Asset Turnover | 0.22 |
| Inventory Turnover | 1.59 |
Taxes
| Income Tax | -212.78M |
| Effective Tax Rate | 0.25 |
Stock Price Statistics
The stock price has increased by 9.74% in the last 52 weeks. The beta is 0.94, so Bio-Rad Laboratories 's price volatility has been higher than the market average.
| Beta | 0.94 |
| 52-Week Price Change | 9.74% |
| 50-Day Moving Average | 341.45 |
| 200-Day Moving Average | 317.57 |
| Relative Strength Index (RSI) | 50.89 |
| Average Volume (20 Days) | 285.88K |
Income Statement
In the last 12 months, Bio-Rad Laboratories had revenue of $2.67B and earned -$637.32M in profits. Earnings per share was $-21.82.
| Revenue | 2.67B |
| Gross Profit | 1.43B |
| Operating Income | 365.70M |
| Net Income | -637.32M |
| EBITDA | -608.26M |
| EBIT | 365.70M |
| Earnings Per Share (EPS) | -21.82 |
Balance Sheet
The company has $403.97M in cash and $1.41B in debt, giving a net cash position of -$1.00B.
| Cash & Cash Equivalents | 403.97M |
| Total Debt | 1.41B |
| Net Cash | -1.00B |
| Retained Earnings | 9.26B |
| Total Assets | 10.60B |
| Working Capital | 2.56B |
Cash Flow
In the last 12 months, operating cash flow was $374.94M and capital expenditures -$156.68M, giving a free cash flow of $218.26M.
| Operating Cash Flow | 374.94M |
| Capital Expenditures | -156.68M |
| Free Cash Flow | 218.26M |
| FCF Per Share | 7.47 |
Margins
Gross margin is 53.58%, with operating and profit margins of 13.69% and -23.86%.
| Gross Margin | 53.58% |
| Operating Margin | 13.69% |
| Pretax Margin | -31.82% |
| Profit Margin | -23.86% |
| EBITDA Margin | -22.77% |
| EBIT Margin | 13.69% |
| FCF Margin | 8.17% |
Dividends & Yields
BIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -6.5% |
| FCF Yield | 2.32% |
Analyst Forecast
The average price target for BIO is $417.5, which is 24.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $417.5 |
| Price Target Difference | 24.3% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Mar 8, 2002. It was a forward split with a ratio of 2:1.
| Last Split Date | Mar 8, 2002 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | 3.15 |
| Piotroski F-Score | 6 |